Blinatumomab combined with low-dose chemotherapy and tyrosine kinase inhibitors as first-line induction for newly diagnosed Philadelphia chromosome-positive B-cell acute lymphoblastic leukemia: improved efficacy and reduced toxicity.

Although the difference in the incidence of infection did not reach statistical significance in this study, this finding may be attributed to the limited sample size.

also in 111,027 other papers

The MRD negativity rate showed a trend toward improvement in the blinatumomab group compared with the conventional chemotherapy group (81.8% [9/11] vs. 46.2% [6/13]).

also in 53,322 other papers